logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Oyster Point Pharma, Inc.

Calculating rank
USPTO Granted Patents = 20


Trademarks = 9

Forward Citations = 97

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal James Donald Loudin (13 out of 47 patents)

silverMedal Kenneth Jason Mandell (13 out of 22 patents)

bronzeMedal Douglas Michael Ackermann, Jr (9 out of 42 patents)

4.  Douglas Michael Ackermann (4 out of 34 patents)

5.  Srinivasa Rao Akireddy (4 out of 14 patents)

6.  Balwinder Singh Bhatti (4 out of 43 patents)

7.  Timothy J Cuthbertson (4 out of 8 patents)

8.  Craig Harrison Miller (4 out of 37 patents)

9.  Joseph Pike Mitchener, Jr (4 out of 7 patents)

10.  Julio A Munoz (4 out of 20 patents)

11.  Pieter Albert Otten (4 out of 7 patents)

12.  Gary Maurice Dull (4 out of 87 patents)

13.  Jeffrey Alan Nau (3 out of 3 patents)

14.  George J Donato (3 out of 3 patents)

15.  John K Lokhnauth (2 out of 2 patents)


20 patents:

1. 12653824 - Compositions and use of varenicline for treating dry eye (2026-06-16),
2. 12576080 - Use of varenicline for treating ocular conditions (2026-03-17),
3. D1055277 - Nasal spray guide (2024-12-24),
4. D1055276 - Nasal spray guide (2024-12-24),
5. 12098018 - Nesting structures for storage, transport, and assembly of drug dispensers and containers (2024-09-24),
6. 11911380 - Compositions and use of varenicline for treating dry eye (2024-02-27),
7. 11903943 - Compositions and use of varenicline for treating dry eye (2024-02-20),
8. 11903942 - Compositions and use of varenicline for treating dry eye (2024-02-20),
9. 11903941 - Compositions and use of varenicline for treating dry eye (2024-02-20),
10. 11542253 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2023-01-03),
11. 11224598 - Methods of increasing lacrimal proteins (2022-01-18),
12. 10919879 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2021-02-16),
13. 10709707 - Methods of treating ocular conditions (2020-07-14),
14. 10456396 - Dry eye treatments (2019-10-29),
15. 10421745 - Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2019-09-24),
Company Overview
Oyster Point Pharma, Inc. is a biotechnology company based in Princeton, NJ, focused on developing innovative therapies for ocular surface diseases. The company specializes in advancing treatments that address unmet medical needs in eye care, particularly in the management of dry eye disease. Through its proprietary drug delivery technologies, Oyster Point aims to enhance patient outcomes and improve the quality of life for individuals suffering from chronic eye conditions. The organization is committed to scientific excellence and patient-centered solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Oyster Point Pharma, Inc. USPTO Patent Assignee Logo
20 Patents

#45 in Princeton, NJ

#619 in New Jersey

#16,426 in US

#31,339 in the World

Princeton, NJ (US)
Princeton, NJ, United States of America

Oyster Point Pharma, Inc.

Forward Citations = 97

19 inventors:

goldMedal James Donald Loudin (13 out of 47 patents)

silverMedal Kenneth Jason Mandell (13 out of 22 patents)

bronzeMedal Douglas Michael Ackermann, Jr (9 out of 42 patents)

4.  Douglas Michael Ackermann (4 out of 34 patents)

5.  Srinivasa Rao Akireddy (4 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oyster Point Pharma, Inc.. Retrieved from https://idiyas.com/company/oyster-point-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…